ICAD Inc
NASDAQ:ICAD

Watchlist Manager
ICAD Inc Logo
ICAD Inc
NASDAQ:ICAD
Watchlist
Price: 1.72 USD 2.08%
Market Cap: 45.6m USD
Have any thoughts about
ICAD Inc?
Write Note

ICAD Inc
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ICAD Inc
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
ICAD Inc
NASDAQ:ICAD
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
PP&E Gross
$116m
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
15%
Inspire Medical Systems Inc
NYSE:INSP
PP&E Gross
$89.3m
CAGR 3-Years
89%
CAGR 5-Years
100%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
PP&E Gross
$24.7m
CAGR 3-Years
40%
CAGR 5-Years
77%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
PP&E Gross
$137.1m
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
14%
W
Waystar Holding Corp
NASDAQ:WAY
PP&E Gross
$71.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ICAD Inc
Glance View

Market Cap
45.3m USD
Industry
Health Care

iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 136 full-time employees. The firm operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). In the Detection segment, the Company’s solutions include advanced image analysis and workflow solutions enables healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, and a comprehensive range of artificial intelligence and computer aided detection (CAD) systems and workflow solutions for two-dimension(2D) and third dimension (3D) mammography, magnetic resonance imaging (MRI) and computed tomography (CT). In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

ICAD Intrinsic Value
1.67 USD
Overvaluation 3%
Intrinsic Value
Price

See Also

Back to Top